ReviewJournal of Cancer2013
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.
Review in Journal of Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04358562 (A Randomized Phase II Trial of Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase II Trial of Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
Who cites it
63 citing papers in PubMed.
- Synthesis of New Pyrazolo[1,5-a]Pyrazin-4(5H)-One Derivatives and Effects on PI3K Protein Levels in A549 Lung Adenocarcinoma Cell Line.Chemistry & biodiversity · 2026Article
- Downregulated CDH3 is correlated with a better prognosis for LUAD and decreases proliferation and migration of lung cancer cells.Genes & genomics · 2024Article
- Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. FromJournal of Cancer · 2024Article
- Chronic Obstructive Pulmonary Disease and Non-Small Cell Lung Cancer an association.Journal of Cancer · 2024Article
- Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial.Journal of cancer research and clinical oncology · 2023Article
- Immunotherapy and Chemotherapy Versus Sleep Disturbances for NSCLC Patients.Current oncology (Toronto, Ont.) · 2023Article
- MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities.Cancers · 2023Review
- Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.Cells · 2022Article
- Radial-EBUS: CryoBiopsy Versus Conventional Biopsy: Time-Sample and C-Arm.International journal of environmental research and public health · 2022Article
- Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.The clinical respiratory journal · 2022Article
- "One Shot" Sample Evaluation of 22G, 22G upgraded, 21G and 19G needle for Endobronchial Ultrasound-EBUS-TBNA.Journal of Cancer · 2022Article
- Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment.Exploration of targeted anti-tumor therapy · 2022Review
- Lung cancer, treatment and nutritional status.Molecular and clinical oncology · 2021Article
- Nucleolar and spindle‑associated protein 1 promotes non‑small cell lung cancer progression and serves as an effector of myocyte enhancer factor 2D.Oncology reports · 2021Article
- Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G.Journal of Cancer · 2021Article
- The clinical significance of RET gene fusion among Chinese patients with lung cancer.Translational cancer research · 2020Article
- CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression.BMC pulmonary medicine · 2020Article
- Inhaled chemotherapy adverse effects: mechanisms and protection methods.Lung cancer management · 2020Review
- Early diagnostic and prognostic value of serum exosomal miR-1246 in non-small cell lung cancer.International journal of clinical and experimental pathology · 2020Article
- Lung cancer biopsies: Comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA.Journal of Cancer · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term "maintenance" treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.